Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 8-10 September 2026
Safety Classified by Officially
CVMP opinions on veterinary medicinal products
The Committee adopted a positive opinion for a marketing authorisation for Cirbloc, for the active immunisation of pigs from three weeks of age to reduce viraemia, virus load in the lungs and lymphoid tissues, and virus shedding caused by porcine circovirus type 2 (PCV2) infection.
The Committee adopted a positive opinion for a marketing authorisation for AviGate S. Typhimurium, for the active immunisation of healthy chickens to reduce faecal excretion and colonisation of internal organs with Salmonella Typhimurium.
The Committee adopted a positive opinion for a variation for Vectormune HVT-AIV, to add turkeys as a new target species and to increase the minimum titre per dose.
The Committee adopted a positiveopinion for a variation for Firocoxib CP-Pharma (firocoxib), to add horses as a new target species.
The Committee adopted a positive opinion for a variation for Innovax ND-H5, to fulfil the specific obligation concerning stability data, by providing the missing data required to support the 36-month shelf-life of the finished product.
The Committee adopted a positive opinion for a variation for Felpreva (tigolaner / emodepside / praziquantel) concerning change(s) to therapeutic indication(s) - addition of a new therapeutic indication or modification of an approved one: treatment of tick infestations with Ixodes hexagonus, Rhipicephalus sanguineus.
The Committee adopted a positiveopinion for a variation for Vectra 3D (dinotefuran / pyriproxyfen / permethrin), concerning change(s) to therapeutic indication(s) - addition of a new therapeutic indication or modification of an approved one: reduction of the risk of infection with the parasite Leishmania infantum transmitted by sand flies (Phlebotomus spp.) for 1 month following administration.
This is an extract. The publication continues at the source.
Source: European Medicines Agency.
Read the original at the source: https://www.ema.europa.eu/en/news/meeting-highlights-committee-veterinary-medicinal-products-cvmp-8-10-september-2026
Officially imported this from European Medicines Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- European Medicines Agency — imported from official source
- Official source
- https://www.ema.europa.eu/en/news.xml RSS
- Imported
- October 03, 2026 20:30
- Versions
- 1 recorded
- Identity
-
https://www.ema.europa.eu/en/news/meeting-highlights-committee-veterinary-medicinal-pro...